Monitoring blood biomarkers in children with kidney transplants
Use of Blood Gene Expression Profile and Donor-derived Cell-free DNA to Monitor Response to Treatment After Biopsy-proven Acute Rejection in Pediatric Kidney Transplant Recipients
This study is testing whether blood tests can help doctors better monitor and treat kidney transplant rejection in children and young adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | N/A to 21 Years |
| Sex | All |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Trial ID | NCT05477082 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of blood biomarkers in monitoring rejection treatment in pediatric kidney transplant recipients who have experienced acute cellular or antibody-mediated rejection. The research focuses on analyzing blood gene expression profiles and donor-derived cell-free DNA to predict acute rejection and assess treatment responses. Participants will include kidney transplant recipients aged 21 years and younger who are undergoing biopsies to investigate potential graft rejection.
Who should consider this trial
Good fit: Ideal candidates for this study are kidney transplant recipients aged 21 years and younger who are undergoing a biopsy for suspected graft rejection.
Not a fit: Patients who are not fluent in English or whose guardians cannot read may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of kidney transplant rejection in pediatric patients.
How similar studies have performed: Similar studies have shown promise in using blood biomarkers for monitoring transplant rejection, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Kidney transplant recipients * Participants undergoing a for-cause kidney biopsy to rule out graft rejection * Ages 21 years and less Exclusion Criteria: * Participants who have opted out of research * Patients, less than 18 years of age, whose parents or legal guardians are illiterate and cannot read. * Participants, 18 years and older, who are illiterate and cannot read. * Participants, less than 18 years of age, whose parents or legal guardians do not speak English. * Participants, 18 years and older, who do not speak English * Participants who are pregnant as confirmed by medical records
Where this trial is running
Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Sarah Kizilbash, MD — University of Minnesota
- Study coordinator: Amy Hanson
- Email: amhanson@umn.edu
- Phone: 612-626-4424
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.